Speaker Profile

Ph.D., CEO, Karius, Inc.

Dr. Kertesz co-founded Karius in 2014 to bring the pathogen detection technology he and colleagues developed at Stanford closer to the bedside. Prior to that, he was the CEO and co-founder of Moleculo, a long-reads DNA sequencing company, which was acquired by Illumina in late 2012. Dr. Kertesz earned an MS in computer science from Tel Aviv University and a PhD in computational biology from the Weizmann Institute of Science. He went on to complete his postdoctoral work in bioengineering at Stanford University, where he developed novel methods for investigating the genetic diversity of human viruses.


Infectious Disease Diagnostics for the Genomic Era
Recent advancements in sequencing technologies, analytical tools and the rapidly growing database of pathogen genome references hold the promise of enabling the simultaneous comprehensive testing of thousands of infectious agents. Key technical, clinical and regulatory challenges must be addressed to bring these powerful tools to the clinic.

Session Abstract – PMWC 2017 Silicon Valley

Session Synopsis: This session will cover the development and validation of clinical next-generation sequencing (NGS) assays for infectious disease diagnosis in precision medicine and highlight the promise, pitfalls, and regulatory / reimbursement issues associated with these emerging tests.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.